Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05121480
Other study ID # EDP1815-207
Secondary ID 2021-001805-63
Status Completed
Phase Phase 2
First received
Last updated
Start date January 31, 2022
Est. completion date March 28, 2023

Study information

Verified date August 2023
Source Evelo Biosciences, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to determine whether the study drug, EDP1815, is safe and effective in the treatment of atopic dermatitis compared with placebo. The study will look at different doses of the study drug, and whether there are differences when the drug is given once daily or twice daily.


Description:

Atopic dermatitis (atopic eczema) is a very common type of skin disease. It typically causes red, dry, and itchy skin and may have a significant impact on quality of life. Rashes may appear on the arms and behind the knees, or anywhere else on the body. While there are existing therapies, there is currently no cure for atopic dermatitis. This is a randomized, double blind, placebo controlled, parallel group, Phase 2 study to evaluate the efficacy and safety of EDP1815 in adult participants 18 to ≤75 years of age with mild, moderate, and severe atopic dermatitis (AD). Participants will be screened within 28 days prior to the first dose of study intervention to confirm study eligibility. Subjects must have mild, moderate, or severe AD involving at least 5% Body Surface Area (BSA); an Investigator Global Assessment (IGA) score of 2, 3, or 4; and an Eczema Area Severity Index (EASI) of at least 6 at screening and Day 1. All participants must agree to use a background therapy (per protocol) twice daily for at least 14 days prior to Day 1 in order to be considered eligible for the study. Approximately 405 participants will be randomized to receive either EDP1815 or placebo (295 to EDP1815: 110 to placebo) and treated for 16 weeks. Participants in Cohorts 1, 2, & 3 will be randomized in a 3:1 ratio (225 to EDP1815: 75 to placebo). Participants in Cohort 4 will be randomized in a 2:1 ratio (70 to EDP1815: 35 to placebo). Cohorts 1, 2 & 3 will be run concurrently, and Cohort 4 recruitment will commence after enrollment for Cohorts 1, 2, & 3 are completed. Randomization will be stratified by baseline disease severity (mild [IGA = 2], moderate [IGA = 3] or severe [IGA = 4] AD). The investigational product will be administered either once or twice daily for 16 weeks. Background emollient (moisturizer) therapy must continue at least twice daily for the duration of the treatment and follow-up periods. Topical rescue therapy is allowed during the treatment period per protocol. The primary efficacy endpoint is achievement of an EASI-50 response at Week 16. Secondary efficacy endpoints will look at EASI, IGA, BSA, SCORAD, DLQI, Pruritus-NRS, Sleep Disturbance-NRS, POEM, and the need for rescue therapy at Weeks 4, 8, 12 and 16 (unless otherwise specified in the protocol). Safety and efficacy assessments will be conducted at the investigator site by a clinical assessor blinded to treatment assignment. Scheduled clinic study visits for all subjects will occur at Screening, Day 1, Week 2, Week 4, Week 8, Week 12, Week 16 (end of treatment) and Week 20 (post-treatment follow-up). Participants discontinuing early from the study will undergo a 28-day follow-up period, where possible. At the end of the 16-week study treatment, qualified participants completing the study will have the option to enter an open label study.


Recruitment information / eligibility

Status Completed
Enrollment 421
Est. completion date March 28, 2023
Est. primary completion date March 9, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Provide written informed consent. - Must meet age criteria. - Must have a diagnosis of atopic dermatitis (AD)for at least 6 months. - Must have severity of atopic dermatitis meeting the below criteria at both Screening and Day 1: - An IGA of 2, 3 or 4 on the vIGA scale, and; - A BSA of =5%, and; - An EASI score of =6. - Must agree to use emollients. - Must meet contraception requirements. Exclusion Criteria: - Have been in a clinical trial for EDP1815 prior to signing of ICF. - Use of phototherapy or tanning beds; systemic medications/treatments that could affect AD or its symptoms including immunosuppressive therapy (e.g., oral or injectable corticosteroids, methotrexate, azathioprine, cyclosporine, mycophenolate mofetil, JAK inhibitors, tacrolimus, and/or leukotriene inhibitor) within 4 weeks of randomization. - Treatment with topical agents that could affect atopic dermatitis, including topical corticosteroids, topical calcineurin inhibitors (e.g., tacrolimus or pimecrolimus), or topical PDE-4 inhibitor (e.g., crisaborole) within 14 days prior to randomization. - Clinically significant abnormalities in screening laboratory values that in the opinion of the Investigator would make a participant unsuitable for inclusion in the study. One retest is permitted within the 28-day screening window. - Hypersensitivity to P histicola or to any of the excipients. - Unwillingness to comply with study procedures, including follow-up, as specified by this protocol, or unwillingness to cooperate fully with the Investigator. - Have any other conditions, which, in the opinion of the Investigator or Sponsor, would make the participant unsuitable for inclusion or could interfere with the participant participating in or completing the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
EDP1815
EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria
Placebo
Placebo oral capsule

Locations

Country Name City State
Australia AUS-102 Carlton
Australia AUS-104 Kogarah
Australia AUS-101 Melbourne
Australia AUS-106 Woolloongabba
Bulgaria BGR-105 Pleven
Bulgaria BGR-104 Sevlievo
Bulgaria BGR-101 Sofia
Bulgaria BGR-102 Sofia
Bulgaria BGR-103 Sofia
Canada CAN-109 Barrie
Canada CAN-108 Edmonton
Canada CAN-105 Markham
Canada CAN-104 Mississauga
Canada CAN-101 Ottawa
Canada CAN-107 Richmond Hill
Canada CAN-103 Surrey
Canada CAN-106 Waterloo
Canada CAN-111 Winnipeg
Germany DEU-105 Berlin
Germany DEU-107 Bochum
Germany DEU-106 Erlangen
Germany DEU-102 Frankfurt am Main
Germany DEU-104 Gera
Germany DEU-101 Hamburg
Germany DEU-103 Heidelberg
Poland POL-104 Gdansk
Poland POL-106 Gdynia
Poland POL-107 Katowice
Poland POL-105 Lódz
Poland POL-101 Lublin
Poland POL-102 Warszawa
Poland POL-103 Wroclaw
United States USA-130 Ann Arbor Michigan
United States USA-119 Baton Rouge Louisiana
United States USA-113 Bellevue Washington
United States USA-131 Birmingham Alabama
United States USA-111 Clarksville Indiana
United States USA-121 Columbus Ohio
United States USA-128 Concord Ohio
United States USA-101 Fort Lauderdale Florida
United States USA-112 Fountain Valley California
United States USA-123 Fremont California
United States USA-117 Frisco Texas
United States USA-124 Jacksonville Florida
United States USA-116 Louisville Kentucky
United States USA-127 Memphis Tennessee
United States USA-109 Metairie Louisiana
United States USA-108 Miami Florida
United States USA-120 Miami Florida
United States USA-105 Miramar Florida
United States USA-114 Newport Beach California
United States USA-102 Orlando Florida
United States USA-110 Pflugerville Texas
United States USA-104 Portland Oregon
United States USA-118 Sandy Springs Georgia
United States USA-125 Silver Spring Maryland
United States USA-115 Sweetwater Florida
United States USA-106 Tampa Florida
United States USA-126 Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Evelo Biosciences, Inc.

Countries where clinical trial is conducted

United States,  Australia,  Bulgaria,  Canada,  Germany,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Achievement of EASI-50 The efficacy of EDP1815 will be measured by achieving a decrease of at least 50% from baseline in Eczema Area Severity Index (EASI) score of 50 (EASI-50) at Week 16. The EASI is a validated measure of eczema severity, which considers a combination of the disease severity and body surface area affected across 4 body regions. The EASI score ranges from 0 - 72. A lower score indicates a better outcome. 16 weeks
Secondary Percentage of Participants Achieving EASI-50 The efficacy of EDP1815 will be measured by the number of participants achieving an EASI-50 at Weeks 4, 8 and 12. The Eczema Area Severity Index (EASI) is a validated measure of eczema severity, which considers a combination of the disease severity and body surface area affected across 4 body regions (arms, legs, trunk, and head/neck). The EASI score ranges from 0 - 72, with a lower score indicating a better outcome. 4, 8 and 12 weeks
Secondary Percentage of Participants Achieving EASI-75 The efficacy of EDP1815 will be measured by the number of participants achieving an EASI-75 at Weeks 4, 8, 12 and 16. The Eczema Area Severity Index (EASI) is a validated measure of eczema severity, which considers a combination of the disease severity and body surface area affected across 4 body regions (arms, legs, trunk, and head/neck). The EASI score ranges from 0 - 72, with a lower score indicating a better outcome. 4, 8, 12, and 16 weeks
Secondary Percentage of Participants Achieving EASI-90 The efficacy of EDP1815 will be measured by the number of participants achieving an EASI-90 at Weeks 4, 8, 12 and 16. The Eczema Area Severity Index (EASI) is a validated measure of eczema severity, which considers a combination of the disease severity and body surface area affected across 4 body regions (arms, legs, trunk, and head/neck). The EASI score ranges from 0 - 72, with a lower score indicating a better outcome. 4, 8, 12, and 16 weeks
Secondary Mean Absolute Change in EASI The efficacy of EDP1815 will be measured using the mean absolute change from baseline in EASI at weeks 4, 8, 12 and 16. The Eczema Area Severity Index (EASI) is a validated measure of eczema severity, which considers a combination of the disease severity and body surface area affected across 4 body regions (arms, legs, trunk, and head/neck). The EASI score ranges from 0 - 72, with a lower score indicating a better outcome. 4, 8, 12, and 16 weeks
Secondary Mean Percentage Change in EASI The efficacy of EDP1815 will be measured using the mean percentage change from baseline in EASI from baseline at weeks 4, 8, 12 and 16. The Eczema Area Severity Index (EASI) is a validated measure of eczema severity, which considers a combination of the disease severity and body surface area affected across 4 body regions (arms, legs, trunk, and head/neck). The EASI score ranges from 0 - 72, with a lower score indicating a better outcome. 4, 8, 12, and 16 weeks
Secondary Percentage of Participants Achieving Investigator's Global Assessment (vIGA) of 0 or 1 With a =2 Point Improvement The efficacy of EDP1815 will be measured by the number of participants achieving a vIGA of 0 or 1 with a =2 Point Improvement from baseline at Weeks 4, 8, 12 and 16 4, 8, 12, and 16 weeks
Secondary Percentage of Participants Achieving vIGA of 0 or 1 The efficacy of EDP1815 will be measured by the number of participants achieving a vIGA of 0 or 1 at Weeks 4, 8, 12 and 16 4, 8, 12, and 16 weeks
Secondary Percentage of Participants Achieving vIGA of 0 The efficacy of EDP1815 will be measured by the number of participants achieving a vIGA of 0 at Week16 16 weeks
Secondary Mean Absolute Change in vIGA*BSA The efficacy of EDP1815 will be measured using the mean absolute change from baseline in vIGA (Validated Investigator Global Assessment) multiplied by the BSA (body surface area) at weeks 4, 8, 12 and 16. 4, 8, 12, and 16 weeks
Secondary Mean Percentage Change in vIGA*BSA The efficacy of EDP1815 will be measured using the mean percentage change from baseline in vIGA (Validated Investigator Global Assessment) multiplied by the BSA (body surface area) at weeks 4, 8, 12 and 16. 4, 8, 12, and 16 weeks
Secondary Mean Absolute Change From Baseline in BSA The efficacy of EDP1815 will be measured using the mean absolute change from baseline in BSA (body surface area) at weeks 4, 8, 12 and 16. The Body Surface Area (BSA) is a measure of the extent of atopic dermatitis at a given time. It is calculated by estimating the number of participant's handprints of active atopic dermatitis are present where one handprint represents 1% body surface area. This higher the BSA %, the more active atopic dermatitis is present. 4, 8, 12, and 16 weeks
Secondary Mean Percentage Change From Baseline in BSA The efficacy of EDP1815 will be measured using the mean percentage change from baseline in BSA (body surface area) at weeks 4, 8, 12 and 16. The Body Surface Area (BSA) is a measure of the extent of atopic dermatitis at a given time. It is calculated by estimating the number of participant's handprints of active atopic dermatitis are present where one handprint represents 1% body surface area. This higher the BSA %, the more active atopic dermatitis is present. 4, 8, 12, and 16 weeks
Secondary Percentage of Participants Achieving BSA-50 The efficacy of EDP1815 will be measured by the number of participants achieving a BSA-50 at Weeks 4, 8, 12 and 16 4, 8, 12, and 16 weeks
Secondary Percentage of Participants Achieving BSA-75 The efficacy of EDP1815 will be measured by the number of participants achieving a BSA-75 at Weeks 4, 8, 12 and 16 4, 8, 12, and 16 weeks
Secondary Percentage of Participants Achieving BSA Reduction to 3% BSA or Less The efficacy of EDP1815 will be measured by the number of participants achieving a BSA reduction to 3% BSA or less at Weeks 4, 8, 12 and 16 4, 8, 12, and 16 weeks
Secondary Mean Absolute Change From Baseline in SCORing Atopic Dermatitis (SCORAD) The efficacy of EDP1815 will be measured using the mean absolute change from baseline in SCORing Atopic Dermatitis (SCORAD) at weeks 4, 8, 12 and 16. The SCORAD is a clinical tool to assess the extent and severity of eczema, to assess treatment effects. There is both an investigator-rated area score using rule of nines to assess disease extent and a disease intensity score comprising erythema, swelling, oozing/crusting, exoriation, lichenification and dryness and a subjective symptoms component which considers itch and sleeplessness scored using a visual analog scale. These scores combine to give a SCORAD score between 0 - 103, with a higher score indicating worse atopic dermatitis. 4, 8, 12, and 16 weeks
Secondary Mean Percentage Change From Baseline in SCORAD The efficacy of EDP1815 will be measured using the mean percentage change from baseline in SCORAD at weeks 4, 8, 12 and 16. The SCORAD is a clinical tool to assess the extent and severity of eczema, to assess treatment effects. There is both an investigator-rated area score using rule of nines to assess disease extent and a disease intensity score comprising erythema, swelling, oozing/crusting, exoriation, lichenification and dryness and a subjective symptoms component which considers itch and sleeplessness scored using a visual analog scale. These scores combine to give a SCORAD score between 0 - 103, with a higher score indicating worse atopic dermatitis. 4, 8, 12, and 16 weeks
Secondary Percentage of Participants Achieving SCORAD-50 The efficacy of EDP1815 will be measured by the number of participants achieving a SCORAD-50 at Weeks 4, 8, 12 and 16 4, 8, 12, and 16 weeks
Secondary Percentage of Participants Achieving SCORAD-75 The efficacy of EDP1815 will be measured by the number of participants achieving a SCORAD-75 at Weeks 4, 8, 12 and 16 4, 8, 12, and 16 weeks
Secondary Mean Absolute Change From Baseline in the Dermatology Quality of Life Index (DLQI) The efficacy of EDP1815 will be measured using the mean absolute change from baseline in the Dermatology Quality of Life Index (DLQI) at weeks 4, 8, 12 and 16. The DLQI is a validated patient reported outcomes instrument comprised of 10 questions to assess how a participant's skin disease has affected their quality of life over the past week. The score ranges from 0 - 30, with a higher score indicating greater impairment of quality of life. A 4-point change from baseline is considered the minimal clinically important difference threshold. 4, 8, 12, and 16 weeks
Secondary Mean Percentage Change From Baseline in DLQI The efficacy of EDP1815 will be measured using the mean percentage change from baseline in the DLQI at weeks 4, 8, 12 and 16. The DLQI is a validated patient reported outcomes instrument comprised of 10 questions to assess how a participant's skin disease has affected their quality of life over the past week. The score ranges from 0 - 30, with a higher score indicating greater impairment of quality of life. 4, 8, 12, and 16 weeks
Secondary Percentage of Participants Achieving a Reduction of =4 in the DLQI, of Those With a Score of =4 at Baseline The efficacy of EDP1815 will be measured by the number of participants achieving a reduction of =4 in the DLQI, of those with a score of =4 at baseline at Week 16. The DLQI score ranges from 0 to 30, with higher scores indicating greater impairment of quality of life. 16 weeks
Secondary Mean Absolute Change From Baseline in Worst Pruritus Numerical Rating Scale (PR-NRS) The efficacy of EDP1815 will be measured using the mean absolute change from baseline in the worst Pruritus Numerical Rating Scale (PR-NRS) at weeks 4, 8, 12 and 16. The PP-NRS is a scale from 0 ("no itch") to 10 ("worse imaginable itch") for participants to rate their worst itch that they have experienced over the previous 24 hours. The value calculated for each visit is the mean of the daily values for the 7 days on and before the visit date as long as at least 4 non-missing scores are available. 4, 8, 12, and 16 weeks
Secondary Percentage of Participants Achieving a Reduction of =2 in the Worst Pruritus-NRS, of Those With a Score of =2 at Baseline The efficacy of EDP1815 will be measured by the number of participants achieving a reduction of =2 in the worst PR-NRS score, of those with a score of =2 at baseline at Weeks 4, 8, 12 and 16. The PP-NRS is a scale from 0 ("no itch") to 10 ("worse imaginable itch") for participants to rate their worst itch that they have experienced over the previous 24 hours. 4, 8, 12, and 16 weeks
Secondary Percentage of Participants Achieving a Reduction of =4 in the Worst PR-NRS, of Those With a Score of =4 at Baseline The efficacy of EDP1815 will be measured by the number of participants achieving a reduction of =4 in the worst PR-NRS score, of those with a score of =4 at baseline at Week 16. The PP-NRS is a scale from 0 ("no itch") to 10 ("worse imaginable itch") for participants to rate their worst itch that they have experienced over the previous 24 hours. 16 weeks
Secondary Mean Absolute Change From Baseline in the Sleep Disturbance Numerical Rating Scale (SD-NRS) Score The efficacy of EDP1815 will be measured using the mean absolute change from baseline in Sleep Disturbance Numerical Rating Scale (SD-NRS) score at weeks 4, 8, 12 and 16. The SD-NRS is a scale from 0 ("best possible sleep") to 10 ("worse possible sleep") for participants to rate their worst sleep that they have experienced over the previous 24 hours. The value calculated for each visit is the mean of the daily values for the 7 days on and before the visit date as long as at least 4 non-missing scores are available. 4, 8, 12, and 16 weeks
Secondary Percentage of Participants Achieving a Reduction of =2 in SD-NRS Score, of Those With a Score of =2 at Baseline The efficacy of EDP1815 will be measured by the number of participants achieving a reduction of =2 in the SD-NRS score, of those with a score of =2 at baseline at Week 16. The SD-NRS is a scale from 0 ("best possible sleep") to 10 ("worse possible sleep") for participants to rate their worst sleep that they have experienced over the previous 24 hours. 16 weeks
Secondary Mean Absolute Change From Baseline in Patient Oriented Eczema Measure (POEM) The efficacy of EDP1815 will be measured using the mean absolute change from baseline in the Patient Oriented Eczema Measure (POEM) at weeks 4, 8, 12 and 16. There are 7 questions scored from 0 (no days) to 4 (every day), giving a POEM score range from 0 to 28, with higher scores representing higher disease severity. 4, 8, 12, and 16 weeks
Secondary Mean Percentage Change From Baseline in Patient Oriented Eczema Measure (POEM) The efficacy of EDP1815 will be measured using the percentage change from baseline in the Patient Oriented Eczema Measure (POEM) at weeks 4, 8, 12 and 16. There are 7 questions scored from 0 (no days) to 4 (every day), giving a POEM score range from 0 to 28, with higher scores representing higher disease severity. 4, 8, 12, and 16 weeks
Secondary Percentage of Participants Achieving a Reduction of =4 in the POEM Score, of Those With a Score of =4 at Baseline The efficacy of EDP1815 will be measured by the number of participants achieving a reduction of =4 in the POEM score, of those with a score of =4 at baseline at Week 16. There are 7 questions scored from 0 (no days) to 4 (every day), giving a POEM score range from 0 to 28, with higher scores representing higher disease severity. 16 weeks
Secondary Number of Courses of Rescue Therapy Per Participant The efficacy of EDP1815 will be measured by the number of rescue therapy courses per participant at Weeks 4, 8, 12 and 16 4, 8, 12, and 16 weeks
Secondary Number of Days of Treatment With Rescue Therapy Per Participant The efficacy of EDP1815 will be measured by the number of rescue therapy treatment days per participant at Weeks 1-8 and 9-16 16 weeks
Secondary Proportion of Participants Not Requiring Rescue Therapy The efficacy of EDP1815 will be measured by the proportion of participants not requiring rescue therapy at Weeks 4, 8, 12 and 16 4, 8, 12, and 16 weeks
See also
  Status Clinical Trial Phase
Completed NCT05018806 - Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Completed NCT04090229 - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis Phase 1
Terminated NCT03847389 - Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Phase 1/Phase 2
Active, not recruiting NCT05388760 - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) Phase 2
Completed NCT05530707 - Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer N/A
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis Phase 3
Recruiting NCT05509023 - Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Phase 2
Recruiting NCT05048056 - Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04598269 - Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis Phase 2
Recruiting NCT03936335 - An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05029895 - A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Terminated NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT04556461 - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Completed NCT03719742 - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer N/A
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Recruiting NCT06366932 - Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models Phase 4
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2